Arrowhead and Janssen Entered into a Licensing Agreement with GSK for JNJ-3989 to Treat Chronic Hepatitis B
Shots:
- As per the agreement, upon closing of the transaction, GSK will take over all the rights & responsibilities of Janssen mentioned under the current licensing agreement b/w Janssen & Arrowhead incl. any outstanding amount to be paid by Janssen to Arrowhead
- Janssen & Arrowhead will receive ~$1B as up front & potential milestone-based payments for the development & commercialization of JNJ-3989 (previously ARO-HBV) plus undisclosed tiered royalties.
- Janssen will oversee carrying out the JNJ-3989 clinical trials at its expense while GSK will handle all upcoming development and commercialization efforts. GSK expects to evaluate JNJ-3989 (HBV-targeted siRNA) in a sequential regimen with bepirovirsen
Ref: GSK | Image: Arrowhead
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
